Identification of important interactions between subchondral bone ...

More documents

Recommendations

Info

Appendix II Publication list 4 first author papers 11 co-Author papers 1 Submitted (first author) Induction of Increased cAMP Levels in Articular Chondrocytes Blocks Matrix Metalloproteinase– Mediated Cartilage Degradation, but Not Aggrecanase-Mediated Cartilage Degradation Morten Asser Karsdal, Eren Ufuk Sumer, Helle Wulf, Suzi H. Madsen, Claus Christiansen, Amanda J. Fosang, and Bodil-Cecilie Sondergaard. ARTHRITIS & RHEUMATISM, Vol. 56, No. 5, May 2007, pp 1549–1558. Patients with Rheumatoid Arthritis have an altered circulatory Aggrecan Profile Jean Charles Rousseau, Eren U Sumer, Gert Hein, Bodil C Sondergaard, Suzi H. Madsen, Christian Pedersen, Thomas Neumann, Andreas Mueller, Per Qvist, Pierre Delmas and Morten A Karsdal. BMC Musculoskeletal Disorders, 2008 May 28;9:74. Cartilage Degradation is Fully Reversible in the Presence of Aggrecanase but not Matrix Metalloproteinase Activity Morten Karsdal, Suzi Madsen, Eren Sumer, Claus Christensen, Kim Henriksen, Amanda Fosang, Bodil Sondergaard. Arthritis Res Ther. 2008;10(3):R63. Epub 2008 May 30 Cartilage formation measured by a novel PIINP assay suggests that IGF-I does not stimulate but maintains cartilage formation ex vivo Suzi H. Madsen, Sondergaard BC, Jensen AC, Morten A Karsdal. Scand J Rheumatol. 2009 May-Jun;38(3):222-6 Appendix II 112 Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, Klickstein L, Aggarwal P, Nemirovskiy O, Byrjalsen I, Qvist P, Bay-Jensen AC, Dam EB, Madsen SH, Christiansen C. Biomarkers. 2009 May;14(3):181-202. Review. Is bone quality associated with collagen age? Leeming DJ, Henriksen K, Byrjalsen I, Qvist P, Madsen SH, Garnero P, Karsdal MA. Osteoporos Int. 2009 Sep;20(9):1461-70. MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation - divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Sondergaard BC, Schultz N, Madsen SH, Bay- Jensen AC, Kassem M, Karsdal MA. Osteoarthritis Cartilage. 2009 Nov 11. [Epub ahead of print] Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments. Wang B, Chen P, Jensen AC, Karsdal MA, Madsen SH, Sondergaard BC, Zheng Q, Qvist P. BMC Res Notes. 2009 Dec 18;2:259.
Biochemical Markers of Joint Tissue Turnover. Bay-Jensen AC, Sondergaard BC, Christiansen C, Karsdal MA, Madsen SH, Qvist P. Assay Drug Dev Technol. 2010 Feb;8(1):118-24 Application of biochemical markers in development of drugs for treatment of osteoarthritis. Qvist P, Christiansen C, Karsdal MA, Madsen SH, Sondergaard BC, Bay-Jensen AC. Biomarkers. 2010 Feb.;15(1):1-19. Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? Bay-Jensen AC, Hoegh-Madsen S, Dam E, Henriksen K, Sondergaard BC, Pastoureau P, Qvist P, Karsdal MA.. Rheumatol Int. 2010 Feb;30(4):435-42. Aggrecanase- and matrix metalloproteinase- mediated aggrecan degradation is associated with different molecular characteristics of aggrecan and separated in time ex vivo. Madsen SH, Sumer EU, Bay-Jensen AC, Sondergaard BC, Qvist P, Karsdal MA. Biomarkers. 2010 May 15(3):266-76 Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. Sondergaard BC, Madsen SH, Segovia-Silvestre T, Paulsen SJ, Christiansen T, Pedersen C, Bay-Jensen AC, Karsdal MA. BMC Musculoskelet Disord. 2010 Apr. 5;11:62. Characterization of an ex vivo femoral head model using bone and cartilage turnover. Suzi Hoegh Madsen, Anne Sofie Goettrup, Gedske Thomsen, Søren Tvorup Christensen, Nikolaj Schultz, Kim Henriksen, Anne-Christine Bay-Jensen, Morten Asser Karsdal. Cartilage. 2011 July; vol. 2, 3: pp. 265-278, first published on October 2010. Appendix II 113 Glucocorticoids exert context-dependent effects on cells of the joint in vitro. Suzi Hoegh Madsen, Kim Vietz Andreassen, Søren Tvorup Christensen, Morten Asser Karsdal, Francis Michael Sverdrup, Anne-Christine Bay-Jensen, Kim Henriksen. Steroids. Acceptet, July 2011 Metalloproteinase and cysteine protease profiles in normal and OA cartilage. Suzi Hoegh Madsen, Kim Henriksen, Søren Tvorup Christensen, Morten Asser Karsdal, Anne- Christine Bay-Jensen. Proteome Science. Submitted, September 2011 Acknowledged for creating figures for papers Matrix metalloproteinase and aggrecanase generated aggrecan fragments: implications for the diagnostics and therapeutics of destructive joint diseases. Sumer, E. U., Qvist, P. and Tankó, L. B. Drug Development Research, 2007, 68: 1–13. Post-translational modifications of the extracellular matrix are key events in cancer progression: Opportunities for biochemical marker development. D. J. Leeming, A. C. Bay-Jensen, E. Vassiliadis, M. R. Larsen, K. Henriksen, and M.A. Karsdal. Biomarkers, 2011; 16(3): 193–205.
Page 1 and 2:
F A C U L T Y O F S C I E N C E U N
Page 3 and 4:
Supervisors University of Copenhage
Page 5 and 6:
Preface Preface The work presented
Page 7 and 8:
Contents Contents Abstract ........
Page 9 and 10:
Abstract Abstract Osteoarthritis (O
Page 11 and 12:
Sammendrag på dansk Sammendrag på
Page 13 and 14:
CHAPTER 1 Objectives CHAPTER 1: Obj
Page 15 and 16:
CHAPTER 2 Introduction CHAPTER 2: I
Page 17 and 18:
2.2 Biology of the joint CHAPTER 2:
Page 19 and 20:
CHAPTER 2: Introduction Also osteob
Page 21 and 22:
CHAPTER 2: Introduction follows nor
Page 23 and 24:
CHAPTER 2: Introduction When the jo
Page 25 and 26:
CHAPTER 2: Introduction Cartilage i
Page 27 and 28:
2.3 The pathology of Osteoarthritis
Page 29 and 30:
CHAPTER 2: Introduction number of a
Page 31 and 32:
CHAPTER 2: Introduction Cysteine pr
Page 33 and 34:
CHAPTER 2: Introduction include car
Page 35 and 36:
2.4 The effect of Glucocorticoids C
Page 37 and 38:
2.5 References for CHAPTER 2 1 WebM
Page 39 and 40:
51 Lorenz H. and Richter W. Osteoar
Page 41 and 42:
97 Nakamura H., Tanaka M., Masuko-H
Page 43 and 44:
139 Garnero P., Ayral X., Rousseau
Page 45 and 46:
CHAPTER 3 Overview of OA models CHA
Page 47 and 48:
CHAPTER 3: Overview of OA models of
Page 49 and 50:
3.3 Ex vivo controls CHAPTER 3: Ove
Page 51 and 52:
19 Brandt K.D. Animal models of ost
Page 53 and 54:
CHAPTER 4 CHAPTER 4: PAPER I PAPER
Page 55 and 56:
266 Cartilage 2(3) therapy for oste
Page 57 and 58:
268 Cartilage 2(3) Figure 1. Charac
Page 59 and 60:
270 Cartilage 2(3) Figure 4. The ca
Page 61 and 62:
272 Cartilage 2(3) Figure 5. Cytoki
Page 63 and 64: 274 Cartilage 2(3) Figure 6. The an
Page 65 and 66: 276 Cartilage 2(3) supports the inc
Page 67 and 68: 278 Cartilage 2(3) release and rece
Page 69 and 70: CHAPTER 5 CHAPTER 5: PAPER II PAPER
Page 71 and 72: leading to fragility fractures [12]
Page 73 and 74: after 1 week (Fig. 2F). The additio
Page 75 and 76: use a range of assays ranging from
Page 77 and 78: still some controversy regarding th
Page 79 and 80: CHAPTER 6 CHAPTER 6: PAPER III PAPE
Page 81 and 82: Biomarkers Downloaded from informah
Page 91 and 92: CHAPTER 7 CHAPTER 7: PAPER IV PAPER
Page 93 and 94: Introduction CHAPTER 7: PAPER IV Ca
Page 95 and 96: Bovine articular cartilage experime
Page 97 and 98: CHAPTER 7: PAPER IV Detection of ke
Page 99 and 100: CHAPTER 7: PAPER IV The MMP inhibit
Page 101 and 102: CHAPTER 7: PAPER IV The pre-stimula
Page 103 and 104: CHAPTER 8 CHAPTER 8: General discus
Page 105 and 106: Future perspectives CHAPTER 8: Futu
Page 107 and 108: Appendix I Co-author declarations f
Page 109 and 110: Appendix I 107
Page 111 and 112: Appendix I 109
Page 113: Appendix I 111
show all

Identification of important interactions between subchondral bone ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?